Primary Sclerosing Cholangitis Clinical Trial
Official title:
Intra-arterial Injection of Umbilical Cord Mesenchymal Stem Cells in Primary Sclerosing Cholangitis
Verified date | April 2018 |
Source | Fuzhou General Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Primary sclerosing cholangitis (PSC) is an idiopathic condition with intrahepatic cholangitis and fibrosis, leading to multifocal bile duct stricture. Its main clinical manifestations are chronic cholestatic lesions and is deemed as autoimmune liver disease. PSC are immune abnormalities that occurs in patients with genetic susceptibility. No other pathogenesis is revealed yet. Ursodeoxycholic acid is used as an empirical treatment, and there is no approved drug or a acceptable treatment regimen. The disease often progresses to liver decompensation and requires liver transplantation. In recent years, the clinical application of stem cell therapy has seen many important advances. Stem cells are characterized with properties of multiple differentiation, repair of damaged tissue and immuno-modulation. This study aims to employ UCMSCs to treat PSC patients and observe its efficacy and safety, and to explore the possible therapeutic mechanisms.
Status | Active, not recruiting |
Enrollment | 20 |
Est. completion date | January 2024 |
Est. primary completion date | January 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - progressive PSC - willing to give consent Exclusion Criteria: - decompensated liver cirrhosis - total serum bilirubin >5ULN - refractory ascites - serum creatinine >1.5mg/dL - Cirrhotic nodules with malignant tendencies - primary biliary cholangitis - IgG4-associated sclerosing cholangitis - non-PSC induced bile duct stones - biliary tract trauma - recurrent suppurative cholangitis - neoplastic disease - pancreatic disease |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Fuzhou General Hospital |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | adverse effects regarding UCMSC infusion | 1 year | ||
Secondary | Pathological score of liver inflammation | 1 year | ||
Secondary | Changes of biliary lesions in magnetic resonance image | softening in stiffness of bile duct | 1 year | |
Secondary | alanine aminotransferase | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02239211 -
A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis
|
Phase 2 | |
Withdrawn |
NCT03216876 -
A Study Of Ursolic Acid For Primary Sclerosing Cholangitis
|
Phase 1 | |
Recruiting |
NCT02605213 -
Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients
|
Phase 4 | |
Recruiting |
NCT01688024 -
Mitomycin C Therapy for Patients With Primary Sclerosing Cholangitis
|
Phase 2 | |
Completed |
NCT03041662 -
Surveillance Study for Early Detection of Cholangiocarcinoma (CCA) in Primary Sclerosing Cholangitis (PSC)
|
||
Completed |
NCT05866809 -
Evaluation of the Safety and Efficacy of HK-660S in Patients With Primary Sclerosing Cholangitis
|
Phase 2 | |
Recruiting |
NCT05618145 -
National Database on Primary Sclerosing Cholangitis (PSC)
|
||
Active, not recruiting |
NCT02446665 -
Disease Status in Primary Sclerosing Cholangitis by Elastography
|
N/A | |
Completed |
NCT02247934 -
Development of a Patient-Reported Outcome Measure to Assess Symptoms in Patients With Primary Sclerosing Cholangitis (PSC)
|
N/A | |
Completed |
NCT01088607 -
Safety and Efficacy Study of Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis
|
Phase 1 | |
Terminated |
NCT01142323 -
Pilot Study of Fenofibrate for PSC
|
Phase 1/Phase 2 | |
Terminated |
NCT04060147 -
Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis
|
Phase 1 | |
Recruiting |
NCT04133792 -
Effect of Simvastatin on the Prognosis of Primary Primary Sclerosing Cholangitis (PSC)
|
Phase 3 | |
Active, not recruiting |
NCT04595825 -
CM-101 in PSC Patients -The SPRING Study
|
Phase 2 | |
Recruiting |
NCT03183570 -
Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT
|
Early Phase 1 | |
Completed |
NCT02943460 -
Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis
|
Phase 2 | |
Completed |
NCT00951327 -
Cholangioscopy Using Narrow Band Imaging (NBI) in Patients With Primary Sclerosing Cholangitis (PSC) Undergoing Endoscopic Retrograde Cholangiopancreatogram (ERCP)
|
N/A | |
Completed |
NCT04024813 -
A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC
|
Phase 2 | |
Recruiting |
NCT05912387 -
Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study
|
Early Phase 1 | |
Completed |
NCT02884557 -
NKT Role in the Regulation of the Inflammatory Bowel Disease
|
N/A |